CRISPR: A Screener's Guide

Overview

Journal SLAS Discov

Publisher Sage Publications

Specialty Molecular Biology

Date 2019 Oct 30

PMID 31658850

Citations 9

Authors

Carlos le Sage

Steffen Lawo

Benedict C S Cross

Affiliations

Soon will be listed here.

Abstract

The discovery of CRISPR-Cas9 systems has fueled a rapid expansion of gene editing adoption and has impacted pharmaceutical and biotechnology research substantially. Here, gene editing is used at an industrial scale to identify and validate new biological targets for precision medicines, with functional genomic screening having an increasingly important role. Functional genomic strategies provide a crucial link between observed biological phenomena and the genes that influence and drive those phenomena. Although such studies are not new, the use of CRISPR-Cas9 systems in this arena is providing more robust datasets for target identification and validation. CRISPR-based screening approaches are also useful later in the drug development pipeline for understanding drug resistance and sensitivity ahead of entering clinical trials. This review examines the developing landscape for CRISPR screening technologies within the pharmaceutical industry and explores the next steps for this constantly evolving screening platform.

Citing Articles

CRISPR-Cas Systems in the Fight Against Antimicrobial Resistance: Current Status, Potentials, and Future Directions.

Ahmed M, Kayode H, Okesanya O, Ukoaka B, Eshun G, Mourid M Infect Drug Resist. 2024; 17:5229-5245.

PMID: 39619730 PMC: 11608035. DOI: 10.2147/IDR.S494327.

Exploring retinal degenerative diseases through CRISPR-based screening.

Li R, Yang F, Chu B, Kong D, Hu J, Qian H Mol Biol Rep. 2024; 51(1):1029.

PMID: 39349793 DOI: 10.1007/s11033-024-09969-6.

Phenotypic drug discovery: recent successes, lessons learned and new directions.

Vincent F, Nueda A, Lee J, Schenone M, Prunotto M, Mercola M Nat Rev Drug Discov. 2022; 21(12):899-914.

PMID: 35637317 PMC: 9708951. DOI: 10.1038/s41573-022-00472-w.

Understudied proteins: opportunities and challenges for functional proteomics.

Kustatscher G, Collins T, Gingras A, Guo T, Hermjakob H, Ideker T Nat Methods. 2022; 19(7):774-779.

PMID: 35534633 DOI: 10.1038/s41592-022-01454-x.

CRISPR based therapeutics: a new paradigm in cancer precision medicine.

Das S, Bano S, Kapse P, Kundu G Mol Cancer. 2022; 21(1):85.

PMID: 35337340 PMC: 8953071. DOI: 10.1186/s12943-022-01552-6.

References

Tan J, Martin S . Validation of Synthetic CRISPR Reagents as a Tool for Arrayed Functional Genomic Screening. PLoS One. 2016; 11(12):e0168968. PMC: 5193459. DOI: 10.1371/journal.pone.0168968. View

Chavez A, Scheiman J, Vora S, Pruitt B, Tuttle M, Iyer E . Highly efficient Cas9-mediated transcriptional programming. Nat Methods. 2015; 12(4):326-8. PMC: 4393883. DOI: 10.1038/nmeth.3312. View

Larson M, Gilbert L, Wang X, Lim W, Weissman J, Qi L . CRISPR interference (CRISPRi) for sequence-specific control of gene expression. Nat Protoc. 2013; 8(11):2180-96. PMC: 3922765. DOI: 10.1038/nprot.2013.132. View

Tzelepis K, Koike-Yusa H, De Braekeleer E, Li Y, Metzakopian E, Dovey O . A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia. Cell Rep. 2016; 17(4):1193-1205. PMC: 5081405. DOI: 10.1016/j.celrep.2016.09.079. View

Aguirre A, Meyers R, Weir B, Vazquez F, Zhang C, Ben-David U . Genomic Copy Number Dictates a Gene-Independent Cell Response to CRISPR/Cas9 Targeting. Cancer Discov. 2016; 6(8):914-29. PMC: 4972686. DOI: 10.1158/2159-8290.CD-16-0154. View

Deans R, Morgens D, Okesli A, Pillay S, Horlbeck M, Kampmann M . Parallel shRNA and CRISPR-Cas9 screens enable antiviral drug target identification. Nat Chem Biol. 2016; 12(5):361-6. PMC: 4836973. DOI: 10.1038/nchembio.2050. View

Sanson K, Hanna R, Hegde M, Donovan K, Strand C, Sullender M . Optimized libraries for CRISPR-Cas9 genetic screens with multiple modalities. Nat Commun. 2018; 9(1):5416. PMC: 6303322. DOI: 10.1038/s41467-018-07901-8. View

Park R, Wang T, Koundakjian D, Hultquist J, Lamothe-Molina P, Monel B . A genome-wide CRISPR screen identifies a restricted set of HIV host dependency factors. Nat Genet. 2016; 49(2):193-203. PMC: 5511375. DOI: 10.1038/ng.3741. View

le Sage C, Lawo S, Panicker P, Scales T, Rahman S, Little A . Dual direction CRISPR transcriptional regulation screening uncovers gene networks driving drug resistance. Sci Rep. 2017; 7(1):17693. PMC: 5735189. DOI: 10.1038/s41598-017-18172-6. View

10.

Farzadfard F, Perli S, Lu T . Tunable and multifunctional eukaryotic transcription factors based on CRISPR/Cas. ACS Synth Biol. 2013; 2(10):604-13. PMC: 3805333. DOI: 10.1021/sb400081r. View

11.

Zhou H, Liu J, Zhou C, Gao N, Rao Z, Li H . In vivo simultaneous transcriptional activation of multiple genes in the brain using CRISPR-dCas9-activator transgenic mice. Nat Neurosci. 2018; 21(3):440-446. DOI: 10.1038/s41593-017-0060-6. View

12.

Maeder M, Linder S, Cascio V, Fu Y, Ho Q, Joung J . CRISPR RNA-guided activation of endogenous human genes. Nat Methods. 2013; 10(10):977-9. PMC: 3794058. DOI: 10.1038/nmeth.2598. View

13.

Perez-Pinera P, Kocak D, Vockley C, Adler A, Kabadi A, Polstein L . RNA-guided gene activation by CRISPR-Cas9-based transcription factors. Nat Methods. 2013; 10(10):973-6. PMC: 3911785. DOI: 10.1038/nmeth.2600. View

14.

Macosko E, Basu A, Satija R, Nemesh J, Shekhar K, Goldman M . Highly Parallel Genome-wide Expression Profiling of Individual Cells Using Nanoliter Droplets. Cell. 2015; 161(5):1202-1214. PMC: 4481139. DOI: 10.1016/j.cell.2015.05.002. View

15.

Datlinger P, Rendeiro A, Schmidl C, Krausgruber T, Traxler P, Klughammer J . Pooled CRISPR screening with single-cell transcriptome readout. Nat Methods. 2017; 14(3):297-301. PMC: 5334791. DOI: 10.1038/nmeth.4177. View

16.

Konermann S, Brigham M, Trevino A, Joung J, Abudayyeh O, Barcena C . Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature. 2014; 517(7536):583-8. PMC: 4420636. DOI: 10.1038/nature14136. View

17.

de Groot R, Luthi J, Lindsay H, Holtackers R, Pelkmans L . Large-scale image-based profiling of single-cell phenotypes in arrayed CRISPR-Cas9 gene perturbation screens. Mol Syst Biol. 2018; 14(1):e8064. PMC: 5787707. DOI: 10.15252/msb.20178064. View

18.

Shalem O, Sanjana N, Hartenian E, Shi X, Scott D, Mikkelson T . Genome-scale CRISPR-Cas9 knockout screening in human cells. Science. 2013; 343(6166):84-87. PMC: 4089965. DOI: 10.1126/science.1247005. View

19.

Hart T, Tong A, Chan K, van Leeuwen J, Seetharaman A, Aregger M . Evaluation and Design of Genome-Wide CRISPR/SpCas9 Knockout Screens. G3 (Bethesda). 2017; 7(8):2719-2727. PMC: 5555476. DOI: 10.1534/g3.117.041277. View

20.

Arroyo J, Jourdain A, Calvo S, Ballarano C, Doench J, Root D . A Genome-wide CRISPR Death Screen Identifies Genes Essential for Oxidative Phosphorylation. Cell Metab. 2016; 24(6):875-885. PMC: 5474757. DOI: 10.1016/j.cmet.2016.08.017. View